OCTREOTIDE INHIBITS THE GROWTH AND DEVELOPMENT OF 3 TYPES OF EXPERIMENTAL LIVER METASTASES

被引：15

作者：

DAVIES, N

KYNASTON, H

YATES, J

NOTT, DM

NASH, J

TAYLOR, BA

JENKINS, SA

机构：

[1] UNIV LIVERPOOL,DEPT SURG,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND

[2] UNIV LIVERPOOL,DEPT PATHOL,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND

来源：

BRITISH JOURNAL OF SURGERY | 1995年 / 82卷 / 06期

关键词：

D O I：

10.1002/bjs.1800820638

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

A study was performed to assess the effects of octreotide on the growth and development of liver metastases in rats. Tumour was induced by intraportal injection of three tumorigenic cell lines (the fibrosarcoma HSN and colonic adenocarcinomas K12/Tr and WB2054M) in syngeneic rats. Octreotide treatment (2 mu g subcutaneously for 3 or 4 weeks) was started 18 h and 1 week after induction; a delay in treatment of 1 week micrometastases to develop. Treatment with octreotide significantly (P < 0.001) reduced the median hepatic replacement of liver by tumour compared with that of control rats given saline (controls: HSN 76.4 per cent, K12/Tr 17.5 per cent, WB2054M 43.9 per cent; octreotide treatment delayed 18 h: HSN 2.7 per cent, K12/Tr 0.6 per cent, WB2054M 1.3 per cent; octreotide treatment delayed 1 week: HSN 9.3 per cent, K12/Tr 2.5 per cent, WB2054M 2.3 per cent). These results clearly indicate that octreotide significantly inhibits the growth and development of experimental liver metastases. Further studies are required both to delineate the mechanism of action and to investigate these effects in a clinical setting.

引用

页码：840 / 843

页数：4

共 27 条

[1]

Resection of the liver for colorectal carcinoma metastases. A multi‐institutional study of indications for resection, Surgery, 103, pp. 278-288, (1988)

[2]

Arbuck SG, Overview of clinical trials using 5‐fluorouracil and leucovorin for the treatment of colorectal cancer, Cancer, 63, pp. 1036-1044, (1989)

[3]

Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D, Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer, BMJ, 306, pp. 752-755, (1993)

[4]

Moertel CG, Fleming TR, MacDonald JS, Et al., Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma, N Engl J Med, 332, pp. 352-358, (1990)

[5]

Evers BM, Parekh D, Townsend CM, Thompson JC, Somatostatin and analogues in the treatment of cancer. A review, Ann Surg, 213, pp. 190-198, (1991)

[6]

Smith JP, Solomon TE, Effects of gastrin, proglumide, and somatostatin on growth of human colon cancer, Gastroenterology, 95, pp. 1541-1548, (1988)

[7]

Nott DM, Baxter JN, Yates J, Et al., Effects of a somatostatin analogue (SMS 201–995) on the growth and development of hepatic tumour derived by intraportal injection of Walker cells in the rat, Br J Surg, 76, pp. 1149-1151, (1989)

[8]

Hemingway D, Grime S, Nott DM, Chang D, Jenkins SA, Cooke T, Hepatic perfusion index: pause for thought, Br J Surg, 76, (1989)

[9]

Martin MS, Martin F, Michiels R, Et al., An experimental model for cancer of the colon and rectum. Intestinal carcinoma induced in the rat with 1, 2‐dimethylhydrazine, Digestion, 8, pp. 22-34, (1973)

[10]

Madara JL, Harte P, Deasy J, Ross D, Lahey S, Steele G, Evidence for an adeno‐carcinoma sequence in dimethyl‐hydrazine‐induced neoplasms of rat intestinal epithelium, Am J Pathol, 110, pp. 230-235, (1983)

← 1 2 3 →